NANO THERAPIES, MEGA RESULTS

Saving lives with targeted

Radiotherapeutics

to treat cancer patients

We are an innovative radiopharmaceutical company developing tumor-specific precision therapeutics. Our  mission is to provide another chance at a cancer-free life for oncology patients.

About Us

  • Our Science

    Our Science

    Our cutting-edge research is focused on the development of meticulously designed nanocarriers, tailored for precise and targeted delivery of therapeutics, backed by a robust global intellectual property portfolio.

  • Our pipeline

    Our Pipeline

    We boast a robust and dynamic product pipeline, encompassing a wide range of innovative concepts progressing seamlessly from early-stage ideation to advanced stages of clinical trial readiness.

  • Our Team

    Our Team

    We are a synergistic alliance of visionary inventors, accomplished entrepreneurs, eminent research scientists, and astute business experts united by shared determination for success and making a positive impact on peoples’ lives.

  • Our Publications and Awards

    Our Publications and Awards

    Our continuous innovation and steadfast commitment to rigorous scientific research are reflected in our extensive array of publications and prestigious awards.

Our Science

Our groundbreaking innovation, XLNT-1, radionuclide 166Ho-containing nanoparticles, meticulously designed to specifically target and combat tumors and metastasis in the peritoneal cavity.

Tumor-specific delivery

    • With most IV administered nanotechnologies, only ~ 0.7% of administered dose reaches tumors.

    • XLNT-1 delivered up to 82% dose/g in tumor tissues.

Tumor tissue penetration

    • Conventionally delivered dose can’t reach deep into tumors; incomplete tumor regression.

    • Radiation emitted from XLNT-1 promotes deep tumor penetration of nanoparticles.

Simple and Scalable manufacturing

    • Scaling the manufacturing of radioactive nanoparticles and liposomes is challenging.

    • The manufacture of XLNT-1 is readily scalable; radioactive XLNT-1 is prepared by a simple neutron-activation process that is conducted just prior to administration to the patient.

Improved treatment outcome of difficult-to-treat cancers

    • Current products offer little significant benefit in treating metastasis, resistance & recurrence.

    • Superior survival has been demonstrated with XLNT-1 targeting metastasis and peritoneal carcinoma.

    • XLNT-1 demonstrated a favorable safety profile in preliminary GLP toxicity studies.

    • XLNT-1 enables clinical SPECT or MR imaging for precise dose determination.

Our Pipeline

Series radiopharmaceuticals for multiple cancers with resistance and metastasis

Our Team

  • Xiuling Lu, PhD

    Xiuling Lu, PhD

    CEO, Co-Founder

    Fellow of American Association of Pharmaceutical Scientists (AAPS).

    Over 16 years experience in drug formulation development, particularly advancing nanotechnologies for cancer therapy.

    She is a distinguished luminary in the realm of nanoparticle-based therapeutics and their corresponding product advancement.

    Key technology inventor with multiple patents

    Professor at the University of Connecticut. She has served of Chair of the Faculty at the National Institute for Pharmaceutical Technology and Education, and presently holds the mantle of Associate Director at the Center for Pharmaceutical Processing Research, concurrently serving as a leader in the AAPS Nanotechnology Community.

  • Michael Jay, PhD

    Michael Jay, PhD

    CSO, Co-Founder

    Over 40 years experience in drug development, imaging agents, and radiopharmaceuticals

    Former director of an FDA-registered cGMP facility

    Founded five companies; one obtained IND for clinical trials

    Professor emeritus at the University of North Carolina at Chapel Hill

  • Ruobing Xia

    Ruobing Xia, MBA/MIA

    CCO, Co-Founder

    Over 20 years experience in big pharma, managed budgets exceeding $100 million

    Led successful product launches resulting in billion-dollar growth

    Founder and board member of multiple startups

    Responsible for global strategy, business development, sales, marketing, and commercial operations.

  • David Worthen, PhD JD

    David Worthen, PhD JD

    Head of R&D

    Served on URI faculty in pharmaceutical science, chemical engineering, and neuroscience

    Senior scientist, project manager, group leader, and principal investigator at BMS, Alcinous Pharmaceuticals, and Yaupon Therapeutics

  • Jeffrey C. Miller, MBA

    Jeffrey C. Miller, MBA

    Business Advisor

    Partner at KASTx Ventures, Co-founder of TSP Therapeutics

    Over 25 years in the bio/pharmaceutical industry across small to large companies

    Worked in over 15 countries, leading both mature and start-up businesses across numerous therapeutic areas spanning rare diseases, oncology, primary and specialty care

  • Al Paz, MBA

    Al Paz, MBA

    Business Advisor

    Founder, President, and CEO of TSP Therapeutics, Inc.

    Nearly four decades experience as a leader in the bio/pharmaceutical industry,

    Working on nearly all sizes of business across 10 therapeutic areas, including four in the Oncology space.

    Conceptualizing and executing market shaping innovations

  • Andrew Salner, MD

    Andrew Salner, MD

    Clinical Advisor

    Medical Director, Hartford HealthCare Cancer Institute at Hartford Hospital

    More than 40 years clinical experience in Radiation Oncology

    American Cancer Society George Sheehan Humanitarian Award

    Lane Adams Quality of Life Award

  • Ron Pion, MD

    Ron Pion, MD

    Clinical Advisor

    Clinical Professor at the UCLA School of Medicine and a Fellow of the American College of Obstetricians and Gynecologists  

    A pioneer in telemedicine and tele-health with more than 30 years of experience.

Our Publications and Awards

Rigorous science with demonstrated consistent outcome:

  • Di Pasqua AJ, Huckle JE, Kim JK, Chung Y, Wang AZ, Jay M and Lu X. Preparation of neutron activatable holmium nanoparticles for the treatment of ovarian cancer metastases. Small. 2012, 8 (7): 997-1000

  • Di Pasqua AJ, Miller ML, Lu X, Peng L, Jay M., Tumor accumulation of neutron activatable holmium-containing mesoporous silica nanoparticles in an orthotopic non-small cell lung cancer mouse model, Inorganica Chimica Acta. 2012, 393: 334–336

  • Di Pasqua AJ, Yuan H, Chung Y, Kim JK, Huckle JE, Li C, Sadgrove M, Tran TH, Jay M, Lu X. Neutron-activatable holmium-containing mesoporous silica nanoparticles as a potential radionuclide therapeutic agent for ovarian cancer. Journal of Nuclear Medicine. 2013, 54:111-116

  • Fu Q, Hargrove D, Lu X.  Improving Paclitaxel Pharmacokinetics by Using Tumor-Specific Mesoporous Silica nanoparticles with Intraperitoneal Delivery. Nanomedicine: Nanotechnology, Biology, and Medicine. 2016, 12: 1951–1959.

  • Kim J, Narayan R, Lu X, Jay M. Neutron-Activatable Needles for Radionuclide Therapy of Solid Tumors. Journal of Biomedical Materials Research Part A. 2017,105(12):3273-3280

  • Kim J, Luo ZX, Wu Y, Lu X, Jay M. In-situ formation of holmium oxide in pores of Mesoporous Carbon Nanoparticles as substrates for neutron-activatable radiotherapeutics . Carbon. 2017, 117: 92–99.

  • Kashfi-Sadabad R, Gonzalez-Fajardo L, Hargrove D, Ahmadi B, Munteanu D, Shahbazmohamadi S, Jay M and Lu X. Engineering multi-functional gold decorated dendritic mesoporous silica/tantalum oxide nanoparticles for intraperitoneal tumor-specific delivery. Particle and Particle Characterization. 2019, 36 (4):1-10

  • D Hargrove, B Liang, R Kashfi-Sadabadi, G N. Joshi, L Gonzalez-Fajardo, S Glass, M Jay, A Salner, X Lu. Tumor-mesoporous silica nanoparticle Interactions Following Intrapritoneal Delivery for Targeting Peritoneal Metastasis. Journal of Controlled Release. 2020 Dec 10;328:846-858

Awards

  • National Institutes of Health (NIH) National Cancer Institute (NCI) STTR Phase I Award

    “Study section has recognized that this is a very significant effort as ovarian cancer is the second most common gynecologic cancer in the United States and new treatment options are needed”.

    - Grant Review Comments

  • National Institutes of Health (NIH) National Cancer Institute (NCI) SBIR Phase II Award

    " The significance is recognized to be high to develop a treatment that is tumor-specific and further reduces side effects” and “the further development of the technology has potential impact to greatly enhance patient outcomes”

    - Grant Review Comments

  • American Cancer Society

    American Cancer Society

    “It is rare to see a drug delivery grant proposal that could actually lead to a clinical treatment, and this is one of them”.

    - Grant Review Comments

Careers

Join Our Team and Make a Difference

We are continuously seeking exceptional talent driven by a passion to make a difference in the lives of our patients and contribute to the success of our business. If you are ready to make a meaningful impact, we invite you to explore the exciting opportunities we have available in following areas:

  • Clinical Research and Development

  • Regulatory Affairs

  • Formulation and PKPD Researchers

  • Business Development

Please don’t forget to check back regularly, as we frequently update our openings and look forward to welcoming new talent.